Kristina Mustonen steps down as Arco Vara CEO

Investing.com -- NCC on Thursday reported fourth-quarter sales of SEK 15,929 million and operating profit (EBIT) of SEK 692 million, while simultaneously announcing significant impairment charges related to property values.

The Swedish construction company is implementing total impairment charges of approximately SEK 1.4 billion, which will impact its fourth-quarter operating profit. Of this amount, SEK 900 million relates specifically to property development.

NCC emphasized that despite these impairment charges, the company delivered strong underlying operating profit in the fourth quarter.

The company also noted that these impairment charges will not affect cash flow or impact NCC’s capacity to distribute dividends to shareholders.

The impairment decision came as part of the company’s year-end closing process, during which NCC reassessed the total property values in its balance sheet.

According to the company, these write-downs are expected to create better conditions for property sales in the near term.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- Mears Group PLC (LON:MER) on Thursday announced in a pre-close trading update that it expects maintenance-led revenues for the fiscal year 2025 to exceed £610 million.

The company also stated that it anticipates its operating margin for FY25 to remain consistent with the prior year.

Additionally, Mears Group reported that it expects management-led revenues for FY25 to be in excess of £500 million.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- Atalaya Mining said on Thursday that copper production exceeded expectations in Q4 2025, with volumes coming in 3% ahead of analyst forecasts, contributing to a strong full-year performance.

The company is expected to report full-year 2025 EBITDA of €183 million, representing a 175% increase year-over-year and 8% above previous estimates.

This performance was driven by better-than-anticipated production volumes and positive provisional pricing impacts.

Atalaya maintained a healthy balance sheet, ending Q4 with a net cash position of €122 million, reflecting robust cash flow generation throughout 2025.

Looking ahead, the company has issued 2026 production guidance of 50-54 thousand tonnes, with output weighted toward the second half of the year.

This guidance came in lighter than expected, prompting analysts to adjust their 2026 volume forecasts to 52 thousand tonnes, down from previous estimates of 54 thousand tonnes.

Despite the reduced 2026 production outlook, analysts have increased their average 2025-2027 EBITDA and EPS estimates by 2% and 3% respectively, citing the company’s strong Q4 performance and improved cash flow generation.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- Galderma and Ipsen have terminated their neuromodulator research and development partnership following an arbitration decision, the companies announced Wednesday.

The partnership, which began in 2014, has been dissolved but the termination only affects Ipsen’s pipeline products. The existing commercial agreements for neuromodulators Dysport and Relfydess will continue under their current terms.

As a result of the arbitration outcome, Galderma will not have rights to Ipsen’s clinical long-acting neurotoxin known as IPN10200. This experimental treatment showed promising results in proof-of-concept data released in September.

Ipsen plans to present complete data for IPN10200 in its first aesthetic indication for glabellar lines during the first half of 2026.

Relfydess has already received regulatory approval in Europe and is awaiting submission to the U.S. Food and Drug Administration.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.